Broader Impact on Rare Diseases and Pharma

The Food and Drug Administration agreed to begin a review of biotech company Moderna’s application to make a new seasonal flu shot available. The decision comes after the FDA initially refused to review the company's application. It's a back and forth that reveals increased turmoil within the agency. WSJ’s Liz Essley Whyte takes us inside the FDA’s unexpected reversals and explores what’s next for the mRNA flu vaccine. Jessica Mendoza hosts. 

Further Listening:

- The FDA Commissioner on Vaccines and Public Trust

- Breakfast Battle: The Cereal Industry vs MAHA

Sign up for WSJ’s free What’s News newsletter.

Learn more about your ad choices. Visit megaphone.fm/adchoices